[at Seeking Alpha] – By David J. Phillips Shares of Endocyte ( ECYT ) fell recently after the company said its lead investigational product, the cancer drug vintafolide – being developed in concert with Merck ( MRK ) – didn’t …
Read more on this.
Merck & Co. … [visit site to read more]
Similar posts:- Pfizer 3rd-qtr profit beats estimates; oncology drugs shine – Pfizer Inc. (NYSE:PFE) [Reuters] – Pfizer Inc reported better-than-expected third-quarter earnings on...
- Johnson & Johnson (NYSE:JNJ) – U.S. guidelines expand potential uses of J&J TB drug [Reuters] – New federal guidelines expand the range of...
- Merck & Co. Inc. (NYSE:MRK) – Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices [Business Wire] – Merck , known as MSD outside...